Zioptan Eyedrops Approved for Glaucoma, Ocular Hypertension

Product should not be used by children or by pregnant women

MONDAY, Feb. 13 (HealthDay News) -- Merck's Zioptan drops (tafluprost ophthalmic solution) have been approved by the U.S. Food and Drug Administration to lower pressure within the eye among people with high blood pressure of the eye (ocular hypertension) or open-angle glaucoma, the most common form of the disease.

Approval was based on five clinical studies involving 905 people, the drug's maker said in a news release. The most common side effects included increased pigmentation of the iris and eyelids, and changes in the thickness and color of the eyelashes.

The product should not be used by children or by pregnant women, Merck warned. It also should be used "with caution" among nursing women and by people with macular edema.

Zioptan should be on pharmacy shelves in March, the Whitehouse Station, N.J., company said.

More information

Medline Plus has more about glaucoma.

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

What internal motivators drive RNs to pursue a BSN?
Nursing2014 , October 2014
Free access will expire on November 24, 2014.


Breast Cancer Risk Assessment in Primary Care
MCN, The American Journal of Maternal/Child Nursing, September/October 2014
Free access will expire on November 10, 2014.


Nurses spurring innovation
Nursing Management, October 2014
Free access will expire on November 10, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events